Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Page 11 paragraph 2.2.12 Regarding claim 8: "Therefor the subject matter of claims 8 is new and inventive."
BOOM - More to come as IP is protected and published!
$OWCP$ is the best company on the OTC. There is so much huge potential being actively developed in the pipeline. In my opinion this PPS level will be a thing of the past by Q3. If the cream hits the market in Q3 or Q4 the PPS will be multiple dollars.
Load up while you can folks.
Keep in mind the last 8K announced a signed agreement with mediq, not a letter of intent. This means OWCP is indeed actively moving forward with making the Psoriasis cream ready for market by Q3 like they have previously announced. So while some of the latest news from OWCP has announced that they will conduct Multiple Myeloma in vitro studies at Sheba Academic Medical Center (WHICH IS HUGE), this 8K means that they continue to take smart steps forward to get the Psoriasis cream on the market meeting their previously announced goals. This latest 8K basically says that OWCP has hired a company that specializes in exactly what will get the OWC Psoriasis cream into the European market the best way possible. Shows solid smart leadership. OWCP is the real deal and appears to be taking all the right measures to set this company up for very big success. It is common sense that his will take time as they continue along, but everything that they do indicates that they are serious in achieving their goals in a way that is most profitable for OWCP. Long investors will be greatly rewarded IMHO.
If you do some solid DD on mediq Innovation Experts GmbH, you will see that this is a real company with management that has been in this field for many years.
The website for mediq is: http://innovationexperts.de
Jan Wende, managing director of mediq. His LinkedIn page is: https://www.linkedin.com/in/jan-wende-361307a/
According to his CV he has 11 years of experience in this type of business including the following information on his business background.
*Partner at MEX - Agency of Medical Experts GmbH May 2006 – Sep 2010
Here is the MEX website: https://www.medicalexperts.de
* In 2011 Jan Wende establishe medIQ Life Science Solutions GmbH - http://www.prweb.com/releases/2012/3/prweb9356177.htm
* The company apparently tweaked it's trademark and name a little and is now mediq Innovation Experts, with Jan Wende as the Managing Director and Founder.
Here is the LinkedIn page for mediq https://www.linkedin.com/company-beta/22294325/
The Managing Director for mediq Innovation Experts (Israel) is David Furst.
His LinkedIn page is: https://www.linkedin.com/in/furstdavid/?ppe=1
$OWCP$$ IS BIG MONEY FOR THE BIG BOYS!
Closed green again today. There is a lot of support here. This stock is ready to run hard.
$OWCP$$ is a money train. Big holders are going to make a lot of $$$$ this summer.
Dr. Yehuda Baruch's "CURRICULUM VITAE AND LIST OF PUBLICATIONS". He has a massive amount of experience.
https://drive.google.com/file/d/0B3CPcGOCWnIPWl9COWw2RURpMDRoaTZEQzRJcjJSRXFSZmw0/view
$OWCP$$ big run coming soon... I can feel it.
Get your OWCP cheapies now before blast off. 8K coming.
$$OWCP$$ big money for the big boys!!!
$$OWCP$$ is money....big things coming...this is one of only otc stocks I see going to nasdaq and high, high pps.
When OWCP gets orphan drug status in 2018 in first or second quarter those of us that took a long position with patience will be greatly rewarded and many will become millionaires.
hod was .84
YES. Anyone wondering about OWCPs potential do your own DD. Not just skim over it but actually dig in and read everything. This company is a phenomenal team set up in the right time and place to utterly capitalize on the biggest emerging market of our lives. Every investment has risk especially in the OTC but if you do solid thorough DD you will realize these guys are the real deal and they would be absolute morons to be trying a scam instead of using their position, experience, and knowledge to grab as much of the MMJ market as they can. They know what they need to do to get as much of the overall MMJ market as they can, and part of that is to not disclose IP prematurely that the competition can use.
If you want to get in a MMJ stock on the ground floor, OWCP IS your once in a lifetime opportunity.
Buy and hold!!!!!
Their website list all SEC filings in the investors section.
http://www.owcpharma.com/investors/
OWCP is extremely coiled up to run hard on a tear. Looking forward to the many catalyst coming soon for this company in this amazing market. Medical MJ is about to explode globally.
Exciting times folks. Once in a lifetime opportunity. Looking back one month from now a 1$ pps will be a bargain price long gone. This stock simply keeps raising it's base as it consolidates. A big run is coming, Good luck.
Normal Patent process taking place here. OWCP is very aware of competition. IP will be disclosed to secure the patents when they are ready to do in a way that protects all of their IP.
Congress just blocked Jeff Sessions from messing with medical marijuana
https://arstechnica.com/science/2017/05/congress-just-blocked-jeff-sessions-from-messing-with-medical-marijuana/
eureka !
IP will be provided to secure the patents when they are ready to do in a way that protects all of their IP. OWCP is very aware of competition.
ON the TOPIC of OWCP; I get the feeling that a lot of people who have been negative on this stock are really eager to BUY THIS STOCK SOON !
Breaking News Mexican Congress Approves Medical Marijuana
http://420meta.com/breaking-news-mexican-congress-approves-medical/
April 30, 2017
There is a cannabis revolution taking place all over the global and we are seeing cannabis reform taking place all around the world.
During the last two years, Brazil, Mexico, Paraguay, Puerto Rico, Canada, Uruguay, Jamaica, Portugal, and the Netherlands have taken steps to legalize or decriminalize cannabis.
Mexico’ Passes Legislation to Legalize Medical Cannabis
On Friday, this trend continued after Mexico’s lower house passed legislation approving the use of medical cannabis. The Health Department will be responsible for creating public policies to regulate the use of medical cannabis and its derivatives.
The legislation allows for the cultivation of cannabis plants for medical and scientific purposes and makes it legal to buy, sell, import and export industrial products with less than 1% THC.
Legislation Sent to Mexico’s President
Mexico has been one of the states to make significant changes to its cannabis laws during the last year. The passing of the legislation on Friday is a major step for the country as it will now go to Mexico’s President Enrique Pena Nieto to be signed into law.
In 2016, the Mexican government decriminalized the possession of small amounts of cannabis and issued permits to cultivate and possess medical cannabis for personal use Last year, the country also started granting permits allowing patients to import medical cannabis products.
A Growing Trend
Over the last month, we have seen a significant increase in the number of cannabis reform initiatives and it is only a matter of time until cannabis is made completely legal.
Although there are concerns regarding what United States Attorney General Jeff Sessions will do to the legal cannabis industry in the United States, the global cannabis industry is not waiting on Sessions to decided and the time to act is now!
Medical cannabis businesses get breathing room after Congress extends key protections
https://mjbizdaily.com/congress-action-medical-cannabis-protections-gives-industry-breathing-space/
By Bart Schaneman
Congress’ decision to pass a $1.1 trillion spending bill that includes key protections for legal medical marijuana businesses is a clear sign the federal government will take a hands-off approach to the MMJ industry – at least in the near term.
As a result, medical cannabis businesses can enjoy a level of certainty for at least six months.
That’s welcome relief for medical marijuana operators given the new Trump administration’s mixed messages about cannabis policy.
But recreational marijuana businesses are still operating in limbo, as the protections don’t extend to the adult-use side of the industry.
News of the extension is expected to encourage investors to keep pumping money into the medical cannabis industry. And the development will reassure business owners in medical cannabis markets that are starting to roll out, such as Hawaii and Maryland.
“It’s important to the industry because it’s one of the first pronouncements from the federal government acknowledging that federal protections are in place for businesses in unambiguous compliance with state law operating in regulated states,” said Ean Seeb, co-founder of Denver Relief Consulting.
The catchall spending bill unveiled Monday extends a policy that prohibits the Justice Department from using federal money to interfere with states’ medical marijuana laws. That provision, previously called the Rohrabacher-Farr Amendment, has been in place since 2014.
Since then, Congress has extended the MMJ amendment several times – including just last week, when it granted an extension of seven days, until May 5.
The new extension – which is expected to be formally approved this week – expires Sept. 30, the expiration date for the spending deal.
To be sure, the long-term legal uncertainty has not evaporated for the marijuana industry. Moreover, the amendment’s language does not extend to recreational laws or businesses, which remain vulnerable to interference by the Justice Department.
Sessions a wild card
U.S. Attorney General Jeff Sessions has been the big wild card for the marijuana industry. The Alabama Republican has issued harsh comments about marijuana, although he recently signaled his department is not about to crack down on the cannabis industry.
Some states have begun taking steps to protect MJ businesses and consumers against any crackdown. And a number of cannabis businesses have put their investment plans on hold in recent months.
“Business owners have slowed down on spending and slowed down on building new cultivation facilities,” said Christie Lunsford, a Denver-based consultant with EndoCannabinoidology. “They’re really mindful about where they’re putting their money, and that’s really smart.”
But, for now, industry officials are heaving a sigh of relief after Congress’ actions on MMJ.
“We are encouraged by the bipartisan support for medical cannabis programs,” said Tai Cheng, chief operating officer of Aloha Green, a vertically integrated medical cannabis business in Honolulu.
“The extension of the amendment … provides emerging medical cannabis dispensary markets with an opportunity to show the public, the patients and the government that state-backed cannabis programs can balance the needs of all parties.”
Matt Abel, a Detroit cannabis attorney, said a client called him just last week concerned about losing federal protections.
“It’s very important that the amendment be reauthorized, otherwise we’re going backwards further into prohibition,” Abel added.
Effect on investors
Despite Trump’s victory, investor interest in cannabis businesses has been growing since the 2016 election. That ultimately could lead to more dollars flowing to cash-squeezed marijuana companies.
Denver cannabis attorney Rachel Gillette, with the firm Greenspoon Marder, said the news from Congress will only increase potential investors’ confidence.
“I don’t think I’ve seen one deal not go through because people were worried about interference from the federal government,” she added.
Seeb agreed, saying “that so long as the protections remain in place, we will not see a decrease in investment. Extending the protections will allow for people who are not experienced with investing in the industry to have mitigated concerns prior to becoming a virgin investor.”
New-market jitters?
Brian Fox, CEO of Greene Fox Enterprises in St. Louis – which has operations in California and Illinois and recently won processing and dispensary licenses in Maryland – said Congress’s move reaffirms his belief that the federal government will not interfere with the medical marijuana industry.
Fox added that the growers he’s been in contact with in Maryland also don’t see federal interference on the horizon and are working to get their businesses up and running as soon as possible. “It’s full steam ahead,” he said.
He also is confident Congress will extend the protection again next September, when it comes up for a vote.
“I believe they’ll keep extending it and they’ll eventually make it permanent,” Fox said.
didn't you already say that???
I'm just speculating... when I read it my first thought was they want to kill the deal on exclusive rights in US so that they can partner with another distributer that would be more advantageous.
OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study
PR Newswire
PETACH TIKVA, Israel, May 3, 2017
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
The purpose of the next phase of the study, which is based upon the promising results of the Company's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future the planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC stated "after in-depth and extensive review and assessment of the study's results accumulated so far, OWC's research committee determined that the medical and scientific accepted multiple myeloma mice model is the best way to progress, compared to other possible known scientific paths. This unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.
The initial OWC study was conducted at the Israeli-renowned Academic Medical Center (affiliated with Tel-Aviv University) using three repetitive tests on the effect of OWC's proprietary cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration). The results from our earlier study demonstrated more than 60% malignant cell death. In view of the basic study results, OWC has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of smoking medical cannabis today which is not widely accepted by scientists and physicians as smoking, edibles and oil extracts with no meaningful or substantial dosage control.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/
Another picture of OWCP at Monaco conference
Live from the Metropole Hotel in Monaco - Spring Edition of Monaco Growth Forums #mgf… https://www.instagram.com/p/BTW9-weBMed/
Load up now while you still have the chance.
I think volume will be higher tomorrow. Up like this each day is perfect.
London/Monaco Growth Conference is underway today. By Wednesday this stock will be on a run.
Load up...
MGF proud to have Dr. Yehuda Baruch as our Keynote Speaker.
OWC Pharmaceutical Research Corp. to Present at Monaco Growth Forums in Monaco
Apr 16, 2017
OWC Pharmaceutical Research Corp. to Present at Monaco Growth Forums in Monaco
Monaco Growth Forums by Andreea Porcelli and OWC Pharmaceutical Research Corp. (OTC– OWCP), are pleased to announce that OWCP has been invited to present at the Monaco Growth Forums Spring Edition on April 25th – 26th at The Montepole Hotel in Monte Carlo, Monaco. During the event, management will introduce OWC Pharmaceutical’s approach to the investment community in Monaco. Dr. Yehuda Baruch, OWCP’s CSO & CTO, will also be a Keynote Speaker at MGF’s Cocktail Reception on Wednesday, April 26th. The keynote topic will be “Cannabis and the Endocannabinoid System: A New and Emerging Pipeline for Medical Products.”
Through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis.
Mr. Mordechai Bignitz , Chairman and CEO commented, “We are very excited to participate in this prestigious European event and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ clinical studies with a specific overview of our unique topical cream for skin conditions, targeting psoriasis first. After publishing our recent news regarding the Pre-Clinical efficacy study findings, concluding that post-application of OWC’s unique, active cannabinoid-based topical cream formulation, there was up to 70% improvement in a variety of inflammation markers directly associated with Psoriasis, we received active inquiries from a variety of leading international scientific institutions in countries like Germany, the Czech Republic, Hungary and more, that adopted or about to adopt MMJ bills. We anticipate that together with some states in the U.S. and Canada. Europe can soon become a primary market for our products.”
Andreea Porcelli, CEO and Founder of Monaco Growth Forums commented, “We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area.”
For more information or to RSVP for the MGF Spring Conference event and one-on-one investor meetings with OWC Pharmaceutical Research Corp., contact Sevinc Bermek, Events Coordinator: sbermek@monacogrowthforums.com or visit https://monacogrowthforums.com/.
The Action of Cannabinoids in Cancer Cells
All I can say is buckle up and take a deep breath because $OWCP$ is blasting off.
This will surely bring deep pocket investors to OWCP. Mordechai Bignitz (Chairman / CEO) and Dr. Yehuda Barach (CSO) listed as speakers on https://monacogrowthforums.com/speakers/
FULL SERIES "WEED 1,2,3"
Dr Sanjay Gupta: Weed - CNN Special Documentary
The Monaco Grown Forums is a very prestigious event with deep pockets and everyone is wanting to get into the MMJ emerging market now. OWCP is being presented as the R&D company at the forefront this market, and with Dr. Yehuda Baruch, OWC's Director of Research and Regulatory Affairs, invited as a Keynote Speaker, this will attract many big investors.
ALL EYES WILL BE ON OWCP all next week.
PPS will going u[ strong INHO.
Mariosmack,
I think it would really help if you study this video... and I mean really study it. After you watch it all the way through, watch it again.
Wow, OWCP is getting a lot of media attention from this Monaco Conference. This will likely be a game changer.
OWC PHARMACEUTICAL RESEARCH CORP (OTCMKTS:OWCP) TO GIVE KEYNOTE IN MONACO
http://stocknewsunion.com/owc-pharmaceutical-research-corp-otcmktsowcp-to-give-keynote-in-monaco/3853/
Companies presented at the Spring 2016 Monaco Growth Forums (MGF). The Pot Stock at that conference TRTC saw a huge and sustained bump in it's PPS right after the conference. Still researching this company to see how much it benefited from the MGF conference, but from the chart, it looks like it did by a lot. http://finance.yahoo.com/quote/TRTC?p=TRTC
NOICE !!!!
Oh yea, this is gonna go over a dollar tomorrow morning IMO. How far it climbs, we shall see.
I can't wait to see this go above $2 next week after the Monaco Conference. The deep pockets there can easily take OWCP to the next level. This is a no brainer.
OWC Pharmaceutical to Discuss Cannabis-based Therapies at Monaco Event
OWC Pharmaceutical Research will give a presentation in Monaco next week on cannabis-based therapies, which studies have shown help people with fibromyalgia, psoriasis and other inflammatory conditions.
Yehuda Baruch, the company’s chief science officer, will talk about “Cannabis And The Endocannabinoid System: A New And Emerging Pipeline For Medical Products,” at the Monaco Growth Forums Spring Edition, April 25-26.
A key aim is to create interest in cannabis-based therapies in Europe, the company acknowledged.
Cannabis-based treatments have been gaining momentum as a valuable option across a growing range of diseases, including fibromyalgia, psoriasis, multiple myeloma, and migraine headaches. OWC is working on appropriate doses and delivery systems for medical cannabis.
Cannabidiol, the plant’s pure molecular compound, has anti-inflammatory and pain-relieving properties, and no known psycho-active effects. Research has shown that cannabidiol can be an effective treatment for many types of pain, particularly inflammatory pain.
Among those who benefit from cannabis pain relief are fibromyalgia patients, studies have shown. One testament to the treatment was an online survey of more than 1,300 fibromyalgia patients in 2016. Many respondents said cannabis did a better job of treating their symptoms than therapies that the U.S. Food and Drug Administration (FDA) has approved.
A clinical trial has shown that a cannabinoid-based therapy also reduced inflammatory markers in psoriasis. The results suggested it could be used against other inflammation-related disorders.
“We are very excited to participate in this prestigious European event, and looking forward to leverage and share more about OWC Pharmaceutical Research Corp., current active MMJ [medical marijuana] clinical studies with specific overview of our unique topical cream for skin conditions, targeting psoriasis first,” Mordechai Bignitz, the CEO of OWC, said in a news release. “We anticipate that together with some states in the U.S. and Canada, Europe can soon become a primary market for our products.”
Andreea Porcelli, CEO of Monaco Growth Forums, added: “We are proud to include OWC in our conference and especially having Dr. Yehuda Baruch as our Keynote Speaker. Founding and leading the Federal Israeli MMJ program, Dr. Baruch obtained worldwide recognition and is one of the most experienced and knowledgeable physicians in that area.”
This is so HUGE for OWCP. There will be so many deeeep pockets at this conference and all eyes will be on OWCP.
Get your cheap shares now while you can.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Topical Cream In Focus
By Brandon Manns / in Medical / on Thursday, 20 Apr 2017 06:04 AM / 0 Comment
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has obtained expressions of interest from the medical and scientific communities globally as a result of its recently reported positive initial clinical efficacy tests data of its topical cream targeting Psoriasis.
The details
OWC Pharmaceutical’s scientific team, directed by the famous Dr. Yehuda Baruch, the firm’s Chief Science Officer previously released trial data and stated that post-application of company’s unique, active CBD-based topical cream, they recorded up to 70% improvement in many inflammation markers directly linked with Psoriasis.
This promising data have led them to expand the scope and size of its clinical study and has resulted in directly to receipt of continuing queries and expressions of interest from investigators world-wide for more data on its topical cream for psoriasis treatment and their product’s expected availability for application in the market.
OWC Pharmaceutical actively protects its IP. It will report the final data, clinical data and relevant protocols after the closure of the full bio-data IP protection. Ziv Turner, the Managing Director of OWC Pharmaceutical, commented that as soon as they closed the efficacy results of their pre-clinical psoriasis cure, the company has continued to get active inquiries from many global scientific institutions in nations like Germany, Hungary, the Czech Republic, and more, that adopted or plan to adopt MMJ bills.
The company is in talks for marketing and scientific cooperation deals. In addition, they realistically anticipate product readiness for their topical cream in initial Q3 2017 and, based on regulatory approvals, states and federal laws they can offer their product to psoriasis patients.
Psoriasis comes in the list of autoimmune diseases, and a patient with psoriasis gets red, scaly patches on the skin. The disease can be related with other grave health conditions, including heart disease, depression and diabetes. Skin cells in psoriasis patients grow at an unusually fast rate, triggering a buildup of lesions that burn and itch.
http://www.mmjobserver.com/owc-pharmaceutical-research-corp-otcmktsowcp-topical-cream-in-focus/28527/